A Novel Approach to Alzheimer’s Drug Therapy, Phase 2a Clinical Trial Results of T3D-959 to be Presented by T3D Therapeutics at CTAD
Research Triangle Park, NC (PRWEB) November 30, 2016 -- T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that CEO, John Didsbury, will be...
T3D Therapeutics Announces Presentation of Phase 2a Preliminary Results of T3D-959 in Alzheimer’s Subjects at the 2016 Alzheimer’s Association International Conference
T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that preliminary Phase 2a data with T3D-959 in mild to moderate Alzheimer’s disease...
T3D Therapeutics Chosen as Late-Breaking Addition to Alzheimer’s Association International Conference to Discuss Rapid Onset of Cognitive Improvement with T3D-959
On Wednesday, July 27th in Toronto, T3D Therapeutics will present Preliminary Results of a 36-patient, two-week Phase 2a Open Label Feasibility Clinical Trial, showing Rapid Onset of Cognitive Improvements in a Subset of Mild and Moderate Alzheimer’s Patients Treated...
T3D Therapeutics Receives FDA Approval for a 6-Month, Open-Label Extension to its Phase 2a Trial of T3D-959 for Treatment of Mild to Moderate Alzheimer’s Disease
T3D Therapeutics has received FDA approval for an open-label, 26-week extension study in mild to moderate Alzheimer’s disease patients extending its Phase 2a feasibility study of T3D-959, an investigational new drug candidate that has the potential to be...
T3D Therapeutics Achieves Key Milestone: Announcing Final Patient Enrolled in a Phase 2a Trial of T3D-959 for Treatment of Mild to Moderate Alzheimer’s Disease
T3D Therapeutics, Inc. has achieved a significant clinical trial milestone in its Phase 2a feasibility study in mild to moderate Alzheimer’s disease patients with T3D-959, an investigational new drug candidate that has the potential to be transformative by slowing,...
T3D Therapeutics to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 16
Research Triangle Park, NC, December 7, 2015 – T3D Therapeutics today announced it will present a company update at the 8th Annual Biotech Showcase conference in San Francisco. The presentation is at the Parc 55 San Francisco, a Hilton hotel on Jan.13, 2016, at 11:15...
T3D Therapeutics to Present at the 1st Annual Neuroscience BioPartnering and Investment Forum in New York City on Feb. 23
Research Triangle Park, NC, December 7, 2015 – T3D Therapeutics today announced it will present a company update at the 1st Annual Neuroscience BioPartnering and Investment Forum conference in New York City. The presentation is at the New York Academy of Sciences on...
John Ratliff Joins T3D Therapeutics’ Advisory Board
John Ratliff recently retired from Quintiles as President and Chief Operating Officer. He led Quintiles’ Global Services organization with it’s clinical research, commercial, consulting, lab operations and was a member of the company’s Board of Directors. John helped...
T3D Therapeutics, Inc. Receives FDA IND Approval to Begin Phase 2 Clinical Study of T3D-959 in Alzheimer’s Patients
Phase 2a Clinical Trial of a Novel Nuclear Receptor Agonist in Alzheimer’s patients expected to initiate in 3Q2015. Read More
T3D Therapeutics Selected by the Alzheimer’s Association to Present Pre-Clinical Results of T3D-959 at the 2015 Alzheimer’s Association International Conference.
T3D Therapeutics, Inc. has been selected by the Alzheimer’s Association to present pre-clinical results of T3D-959 at the upcoming Alzheimer’s Association International Conference (AAIC) in Washington, DC, July 18-23, 2015. The poster presentation will provide details...